Brenner, who has worked in the FDA’s Center for Devices and Radiological Health, will lead the agency until a permanent ...
Up to €37.5m of Median’s funding comes from the EIB, and €10m from an equity line with IRIS Capital Investment.
GlobalData on MSN2d
Stealth faces another hurdle as FDA delays decision on Barth syndrome drugThe FDA rejected the company’s initial NDA in 2021, citing the lack of an adequate trial to demonstrate efficacy.
GlobalData on MSN5d
FDA lifts clinical hold on Amylyx’s Phase I ALS trialThis is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback